Company Analysis
Sign in

TransCode Therapeutics, Inc. (RNAZ)

Nasdaq: RNAZ · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2020
Full chart Alerts Compare
Grade2.9
◀ Past 2.4● Present 1.7▶ Future 4.3
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Who owns TransCode Therapeutics, Inc.

As filed with the SEC
Holders of 5% or more
6
Defj, LLC holds 83.9% of Common Stock, as its SCHEDULE 13D/A filed Aug 3, 2026 says.
Directors and officers
4
report now, of 9 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Defj, LLC
SCHEDULE 13D/A · filed Aug 3, 2026 · Common Stock · 83.9% in Jul 27, 2026
83.9%
Unleash Immuno Oncolytics, Inc.
SCHEDULE 13G · filed Jul 28, 2026 · Common Stock, par value $0.0001 per share
9.94%
YA II PN, Ltd.
SCHEDULE 13G · filed Apr 20, 2026 · Common Stock, $0.0001 par value per share
9.9%
Elena Rosa Braci
SCHEDULE 13G · filed Jul 28, 2026 · Common Stock, par value $0.0001 per share
6.17%
Daniel Eduardo Katzman
SCHEDULE 13G · filed Jul 28, 2026 · Common Stock, par value $0.0001 per share
5.16%
Thomas Joseph Tracy
SCHEDULE 13D · filed Mar 20, 2025 · Common Stock, par value $0.0001 per share
5%
Sabby Management, LLC
SCHEDULE 13G/A · filed Jan 7, 2026 · Common Stock · reported falling below 5%, from 9.9% in Jan 3, 2025
under 5%
Anson Funds Management LP
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, $0.0001 par value · reported falling below 5%, from 9.9% in Feb 14, 2025
under 5%
Goldman Sachs Group Inc.
SCHEDULE 13G/A · filed Nov 10, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.9% in Aug 14, 2025
under 5%
What RNAZ reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Abcj, LLC
A company bought · acquisition · Sep 2025 · owns, named in the 10-K filed Apr 15, 2026
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2223
2023 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.
SI Assistanton RNAZ · research, not advice